Healio (10/28, Monostra) reports researchers wrote in a study that “GLP-1s hold promise as a potential treatment for alcohol and substance use disorders.” The researchers “discussed how GLP-1s are tied to several changes in the central nervous system and suggested the activation of GLP-1 receptors could reduce ‘drug-seeking and consummatory behaviors.’” They wrote “that some studies have found certain forms of obesity have phenotype characteristics that resemble addiction. Additionally, some therapies used to treat alcohol or substance use disorders, such as naltrexone and topiramate, are also used for obesity.” They called for “more research, including more studies to assess the mechanisms of GLP-1s as they relate to substance use disorders and more randomized controlled trials to evaluate efficacy and safety.” The studywas published in the Journal of the Endocrine Society.
Related Links:
— “GLP-1s may offer ‘real impact’ for treating alcohol and substance use disorders,”Michael Monostra, Healio, October 28, 2025